SCHEMBL2720141

SCHEMBL2720141

CCOC(=O)c1cnc2ccccc2c1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.61
SMN1; SMN2 Q16637 6/20 0.61
MAPT P10636 5/20 0.61
HTT P42858 3/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
LMNA P02545 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
PKM P14618 1/20 0.59
MAPK1 P28482 1/20 0.59
ATM Q13315 1/20 0.59
NPC1 O15118 1/20 0.57
TP53 P04637 1/20 0.57
RAB9A P51151 1/20 0.57
KDM4E B2RXH2 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP2C9 P11712 2/20 0.57
HPGD P15428 2/20 0.57
CYP2C19 P33261 2/20 0.57
CYP3A4 P08684 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31312807 0.87 MEN1 (0.55) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1194152 0.87 MEN1 (0.52) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL31312837 0.85 MEN1 (0.53) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL31312734 0.85 MEN1 (0.53) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL8786827 0.85 MEN1 (0.58) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL1194582 0.85 NMT1 (0.52) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL31312996 0.83 MEN1 (0.51) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1193674 0.83 MAPT (0.51) ALDH1A1SMN1; SMN2MAPTHTTMEN1
SCHEMBL15445432 0.83 KMT2A (0.64) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3074877 0.82 THRB (0.56) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431240-A Preparation method and application of chiral 1, 4-dihydroquinoline 南开大学 2025-02-14 CN disclosed
EP-3510025-B1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2022-06-29 EP disclosed
EP-3510025-B1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2022-06-29 EP disclosed
CN-110248934-B Heteroaryl PAD4 inhibitors 帕德罗科治疗公司 2022-05-24 CN disclosed
CN-113121427-B Quinoline derivative and preparation method and application thereof 广东工业大学 2022-04-01 CN disclosed
US-20210299115-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-09-30 US disclosed
US-20210299115-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-09-30 US disclosed
CN-113121427-A Quinoline derivative and preparation method and application thereof 广东工业大学 2021-07-16 CN disclosed
US-11026937-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-06-08 US disclosed
US-11026937-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-06-08 US disclosed
EP-3510025-A1 HETEROARYL INHIBITORS OF PAD4 Padlock Therapeutics, Inc. (US) 2019-07-17 EP disclosed
WO-2018049296-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-03-15 WO disclosed
US-20140031355-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2014-01-30 US disclosed
US-20140031355-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2014-01-30 US disclosed
EP-2635565-A1 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS Amgen Inc. (US) 2013-09-11 EP disclosed
WO-2012061696-A1 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS AMGEN INC. (US) 2012-05-10 WO disclosed
WO-2012061696-A1 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS AMGEN INC. (US) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299115-A1 HETEROARYL INHIBITORS OF PAD4 PADI4, PADI1, PADI6 ALDH1A1 956/4885SMN1; SMN2 3573/4885MAPT 3883/4885
US-11026937-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 ALDH1A1 956/4885SMN1; SMN2 3573/4885MAPT 3883/4885
US-20140031355-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, SSB, MALT1 ALDH1A1 3702/4885SMN1; SMN2 385/4885MAPT 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.